Matt Zuga Sells 6,888 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CFO Matt Zuga sold 6,888 shares of Acumen Pharmaceuticals stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $1.82, for a total transaction of $12,536.16. Following the completion of the sale, the chief financial officer owned 209,951 shares of the company’s stock, valued at $382,110.82. This represents a 3.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Matt Zuga also recently made the following trade(s):

• On Wednesday, January 7th, Matt Zuga sold 5,805 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.99, for a total transaction of $11,551.95.
• On Tuesday, January 6th, Matt Zuga sold 5,100 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.97, for a total transaction of $10,047.00.
• On Monday, January 5th, Matt Zuga sold 4,000 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.96, for a total transaction of $7,840.00.

Acumen Pharmaceuticals Price Performance

NASDAQ ABOS opened at $1.73 on Wednesday. The stock has a market capitalization of $104.79 million, a price-to-earnings ratio of -0.78 and a beta of 0.23. Acumen Pharmaceuticals, Inc. has a 1-year low of $0.86 and a 1-year high of $2.46. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.02 and a quick ratio of 6.02. The business’s fifty day moving average price is $1.93 and its 200-day moving average price is $1.69.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.19. On average, equities analysts predict that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Trending Headlines about Acumen Pharmaceuticals

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Positive Sentiment: Analyst and institutional support — ABOS carries a consensus “Moderate Buy” from sell‑side analysts with a consensus price target near $6.75, and several institutions have recently built or increased stakes (Hudson Bay, SG Americas, Susquehanna, Bank of America). This underpins longer‑term demand and may limit downside. MarketBeat Coverage
• Neutral Sentiment: Short‑interest data is reported as effectively zero for Jan. 12, but the published figures contain inconsistencies (NaN); the short‑interest snapshot is unreliable and should not be relied on for explaining intraday moves. Monitor future updates for clarity.
• Neutral Sentiment: Insiders retain large holdings — despite recent sales, CEO Daniel O’Connell still owns ~593k shares, CFO Matt Zuga ~210k and COO Russell Barton ~123k. Large remaining insider stakes can be seen as alignment with shareholders even after sales.
• Negative Sentiment: Clustered insider selling — multiple senior executives sold shares between Jan. 5–12. CEO Daniel O’Connell sold ~26,472 shares across three trades (avg prices roughly $1.73–$1.82), CFO Matt Zuga sold 6,888 shares at $1.82 (and additional small sales earlier in the week), and COO Russell Barton sold 3,530 shares at $1.86. The concentration of sales (roughly ~37k shares total) is likely weighing on near‑term sentiment. SEC filings and press coverage: SEC Form 4 AmericanBankingNews: CEO sale
• Negative Sentiment: CFO’s repeated small sales — Matt Zuga executed multiple sales in early January (Jan. 5–8) at prices between ~$1.96–$1.82, totaling roughly $40k–$45k across those trades; repeated disposals can be interpreted negatively by active traders. Coverage: InsiderTrades alert

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ABOS. Bank of America lowered their price objective on shares of Acumen Pharmaceuticals from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Wall Street Zen upgraded shares of Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research report on Friday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.75.

Institutional Investors Weigh In On Acumen Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in Acumen Pharmaceuticals during the third quarter valued at approximately $691,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Acumen Pharmaceuticals during the 2nd quarter valued at $291,000. Jane Street Group LLC lifted its stake in shares of Acumen Pharmaceuticals by 1,526.0% during the 2nd quarter. Jane Street Group LLC now owns 175,670 shares of the company’s stock valued at $204,000 after buying an additional 164,866 shares in the last quarter. Marshall Wace LLP bought a new position in Acumen Pharmaceuticals in the 2nd quarter worth $160,000. Finally, Bridgeway Capital Management LLC increased its stake in Acumen Pharmaceuticals by 65.1% in the 3rd quarter. Bridgeway Capital Management LLC now owns 190,171 shares of the company’s stock worth $325,000 after buying an additional 75,000 shares in the last quarter. Institutional investors own 71.01% of the company’s stock.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.